
OSTX Stock Forecast & Price Target
OSTX Analyst Ratings
Bulls say
OS Therapies is positioned for success, with a strong focus on addressing the unmet need for treatments in osteosarcoma and other solid tumors, as highlighted by their innovative pipeline and mission-driven approach. The company has robust clinical and regulatory momentum, with upcoming meetings and expected initiation of a confirmatory Phase 3 trial. Additionally, multiple regulatory designations and potential for a priority review voucher provide a strong foundation for expedited development and future financial opportunities.
Bears say
OS Therapies is facing significant regulatory challenges with its Phase 3 launch in 2026, as the company must align with multiple agencies and conduct a global confirmatory trial for its potential cancer treatment. This timeline may result in delays and higher costs, further impacting the company's financial stability. Additionally, OS Therapies is currently in the preclinical stages for its other product candidate, OST-tADC, and has not yet generated any revenues, making it a risky investment.
This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.
OSTX Analyst Forecast & Price Prediction
Start investing in OSTX
Order type
Buy in
Order amount
Est. shares
0 shares